NASDAQ:MDGL Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $231.06 -14.58 (-5.94%) (As of 03/22/2023 05:24 PM ET) Add Compare Share Share Today's Range$230.56▼$246.3150-Day Range$238.81▼$307.0852-Week Range$57.15▼$315.45Volume370,732 shsAverage Volume428,024 shsMarket Capitalization$4.19 billionP/E RatioN/ADividend YieldN/APrice Target$294.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Madrigal Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside25.7% Upside$294.75 Price TargetShort InterestBearish7.43% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.58Based on 3 Articles This WeekInsider TradingSelling Shares$20.41 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($19.59) to ($11.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector572nd out of 983 stocksPharmaceutical Preparations Industry274th out of 478 stocks 3.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $294.75, Madrigal Pharmaceuticals has a forecasted upside of 25.7% from its current price of $234.45.Amount of Analyst CoverageMadrigal Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.43% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 3.1 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Madrigal Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest26 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,414,070.00 in company stock.Percentage Held by Insiders24.49% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.98% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($19.59) to ($11.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -13.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -13.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 20.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.Read More Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Stock News HeadlinesMarch 22, 2023 | marketbeat.comWant Diversified Upside in Biotechnology? Check out LABU (MDGL)Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.March 20, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Analysts at StockNews.comMarch 22, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 10, 2023 | finance.yahoo.comIntercept Tumbles As Its Experimental NASH Drug Faces Yet Another ObstacleMarch 10, 2023 | msn.comIntercept to face FDA AdCom meeting on NASH candidate in MayFebruary 26, 2023 | uk.finance.yahoo.comMDGL Mar 2023 305.000 callJanuary 30, 2023 | finance.yahoo.comMadrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To ProfitJanuary 20, 2023 | finance.yahoo.comIntercept's (ICPT) NDA for NASH Treatment Accepted By FDAMarch 22, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 14, 2023 | seekingalpha.comMDGL Madrigal Pharmaceuticals, Inc.January 9, 2023 | msn.comHere's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 YearsJanuary 7, 2023 | finance.yahoo.comTop Picks 2023- Madrigal Pharmaceuticals MDGLJanuary 6, 2023 | finance.yahoo.comMadrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver FibrosisJanuary 3, 2023 | benzinga.comThis Is What Whales Are Betting On Madrigal PharmaceuticalsJanuary 3, 2023 | bizjournals.comWith stock up 350%, Madrigal secures more than $300M to advance NASH drug candidateDecember 26, 2022 | seekingalpha.comMadrigal Pharmaceuticals Setting The StandardDecember 26, 2022 | finance.yahoo.comThis Stock That Tripled in 2022 Could Rocket Even Higher in 2023December 23, 2022 | finance.yahoo.comWhy Madrigal Pharmaceuticals Was a Top Stock This WeekDecember 22, 2022 | finance.yahoo.comBiotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & MoreDecember 21, 2022 | seekingalpha.comMadrigal: Next Steps After 'Wow' Data In NASHDecember 21, 2022 | seekingalpha.comMadrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 SuccessDecember 21, 2022 | finance.yahoo.comMeet the Biotech Stock That Jumped Over 260% in One DayDecember 20, 2022 | msn.comPeering Into Madrigal Pharmaceuticals's Recent Short InterestDecember 20, 2022 | msn.com$1000 Invested In Madrigal Pharmaceuticals 5 Years Ago Would Be Worth This Much TodayDecember 20, 2022 | markets.businessinsider.comAnalyst Ratings for Madrigal PharmaceuticalsDecember 20, 2022 | msn.comHere's How An Options Trader Made $5.5 Million In One DayDecember 20, 2022 | finance.yahoo.comEstimating The Fair Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Company Calendar Last Earnings2/23/2023Today3/22/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees71Year Founded2011Price Target and Rating Average Stock Price Forecast$294.75 High Stock Price Forecast$390.00 Low Stock Price Forecast$151.00 Forecasted Upside/Downside+20.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($17.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-295,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-270.13% Return on Assets-123.03% Debt Debt-to-Equity Ratio0.25 Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.54 per share Price / Book21.29Miscellaneous Outstanding Shares18,140,000Free Float13,696,000Market Cap$4.46 billion OptionableOptionable Beta-0.55 Social Links Key ExecutivesPaul A. FriedmanChairman, President & Chief Executive OfficerAlex G. HowarthChief Financial OfficerEdward ChiangSVP-Clinical & Technical OperationsRebecca A. TaubDirector & Chief Medical OfficerStephen DodgeSenior Vice President-Global Medical AffairsKey CompetitorsAlkermesNASDAQ:ALKSIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCBought 2,835 shares on 2/28/2023Ownership: 0.070%Parallax Volatility Advisers L.P.Bought 23,000 shares on 2/27/2023Ownership: 0.000%NatixisBought 1,178 shares on 2/24/2023Ownership: 0.007%Macquarie Group Ltd.Sold 849 shares on 2/21/2023Ownership: 0.167%Alliancebernstein L.P.Bought 8,268 shares on 2/16/2023Ownership: 0.146%View All Insider TransactionsView All Institutional Transactions MDGL Stock - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price forecast for 2023? 11 Wall Street analysts have issued twelve-month target prices for Madrigal Pharmaceuticals' stock. Their MDGL share price forecasts range from $151.00 to $390.00. On average, they anticipate the company's stock price to reach $294.75 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2023? Madrigal Pharmaceuticals' stock was trading at $290.25 at the start of the year. Since then, MDGL shares have decreased by 16.9% and is now trading at $241.27. View the best growth stocks for 2023 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings data on Thursday, February, 23rd. The biopharmaceutical company reported ($4.98) EPS for the quarter, missing analysts' consensus estimates of ($4.61) by $0.37. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA Healthcare Momentum ETF (PTH), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Alger Mid Cap 40 ETF (FRTY). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (9.71%), Avidity Partners Management LP (2.51%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.38%), Artisan Partners Limited Partnership (1.24%) and Armistice Capital LLC (1.22%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $241.27. How much money does Madrigal Pharmaceuticals make? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.38 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($17.23) on an earnings per share basis. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228. This page (NASDAQ:MDGL) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.